FAME II data confirms large opporutnity for FFR, says Piper Jaffray

theflyonthewall.com

Piper Jaffray says the St. Jude Medical (STJ)-sponsored FAME II study of Fractional Flow Reserve, or FFR, in patients with stable coronary artery disease confirm a large market opportunity for Fractional Flow Reserve. Piper believes the data results will move FFR from Class IIA in the U.S. to Class IA. The firm keeps an Overweight rating on shares of St. Jude Medical, and says the results also benefit Volcano (VOLC), a pure play in the FFR space.

View Comments